Healthy Returns: Chinese obesity drug emerges as a... CNBC

Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly’s Zepbound

CNBC July 16, 2025

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki's nonprofit acquires 23andMe.

Comments 0

Log in to post a comment.

No comments yet. Be the first to comment!

Advertise with Us

Reach our audience with your ads